About Us
Meet the Team
Conditions & Procedures
Conditions
Procedures
Patient Center
Research
Education & Training
News & Events
New Lung Cancer Test Better Predicts Survival
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a molecular test can better predict the likelihood of death from early-stage lung cancer versus conventional clinico-pathologic staging.
New Lung Cancer Assay Ready for Prime Time
Make a Gift
A gift to the Thoracic Oncology Progam helps us discover new treatments and cures for lung cancer, esophageal cancer and mesothelioma.
Michael Mann, M.D.
Associate Professor of Surgery
Division of Adult Cardiothoracic Surgery
Chief of General Thoracic Surgery, San Francisco VA Medical Center
Contact Information
BiographyEducation
- 1981-85, Princeton University, A.B. , Chemistry
- 1985-91, Stanford University, MD , Medicine
Residencies
- Stanford University, Intern, Surgery
- Stanford University, Resident, General Surgery
- Brigham and Women's Hospital/Harvard Medical School, Resident, General Surgery
- University of California, San Francisco School of Medicine, Resident, Cardiothoracic Surgery
Fellowships
- Stanford University, Postdoctoral Fellow
- NIH Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship, Cardiovascular Disease
Board Certification
- American Board of Surgery
- American Board of Thoracic Surgery
Program Affiliations
- Heart and Lung Transplantation Program
- Thoracic Oncology Program
- UCSF Cardiovascular Research Institute
- UCSF Helen Diller Family Comprehensive Cancer Center
Clinical Expertise
- Bronchioloalveolar Carcinoma (BAC)
- Carcinoid Tumors
- Chest Wall Tumors
- Esophageal Cancer
- Esophagectomy
- Lung Metastases
- Lung Transplantation
- Lung Volume Reduction Surgery
- Malignant Mesothelioma
- Mediastinal Masses
- Minimally Invasive Thoracic Surgery
- Non-Small Cell Lung Cancer
- Sarcomas
- Small-Cell Lung Cancer
- Tracheal Tumors
- Video-Assisted Thoracoscopic Surgery (VATS)
Research Interests
- Personalized Medicine
- Cardiovascular cell cycle biology
- Cardiovascular tissue engineering
- Molecular and stem cell biology
- Molecular genetics of heart disease
- Myocardial gene therapy
- Stem and progenitor cell transplantation for cardiovascular regeneration
- Therapeutic neovascularization for ischemic disease
Biography
Michael Mann, M.D. joined the Thoracic Oncology Program in 2003 as a cardiothoracic surgeon. He received his M.D. from Stanford University and was awarded a Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship through the NIH. Dr. Mann completed his General Surgery residency at Brigham and Women's Hospital/Harvard Medical School and his Cardiothoracic Surgery fellowship at UCSF.
Dr. Mann is Chief of Thoracic Surgery at the San Francisco VA Medical Center and an attending surgeon at the UCSF Medical Center. His areas of expertise include lung cancer, mesothelioma, esophageal cancer, sarcoma and minimally invasive (video-assisted) thoracoscopic surgery. He also has expertise in performing cardiac procedures including coronary bypass, valve replacement, and aortic reconstruction.
Dr. Mann is widely admired for his teaching skills and is Assistant Director of the Thoracic Surgery Training Program. He holds memberships in numerous professional organizations including the Society of Thoracic Surgeons, American College of Surgeons, American Heart Association, American College of Cardiology and the Massachusetts Medical Society. Highly respected by his peers, Dr. Mann was named to the list of U.S. News "Top Doctors," which denotes the top 10% of physicians within a region practicing a given specialty. He has received numerous awards including the Cardiovascular Medicine Award for Excellence in Research, Dean's Award for Excellence in Research, and William Randolph Hearst Endowment for Young Investigators. Dr. Mann also serves as a scientific reviewer for numerous professional journals.
While on the faculty at Harvard Medical School, Dr. Mann founded the Cardiovascular Gene Therapy Group. He also invented several novel drug and delivery technologies and helped pioneer the application of gene regulation and vascular biology principles to the problem of coronary bypass graft failure. This led to one of the first large scale programs to evaluate the integration of molecular therapy into cardiac surgery.
Dr. Mann's research in genetic and molecular therapies has been widely recognized. He is currently an Associate Investigator in the UCSF Cardiovascular Research Institute. Dr. Mann also serves as a scientific advisor to the American Heart Association, the NIH Recombinant-DNA Advisory Committee, and to numerous device and pharmaceutical companies.
Research Summary
The Cardiothoracic Translational Research Laboratory is focused on turning a deeper understanding of the complex biology of failing heart cells into a new generation of cellular and molecular therapies that may actually reverse the ravages of heart failure. This lethal condition affects more than 5 million Americans and is already the greatest single economic burden in American health care, yet no existing therapies can either halt or reverse the disease process.
Michael J. Mann, M.D. is the Lab Director. His group is analyzing the molecular basis of the failing heart's response to non-embyonic stem cell transplantation, and these results will provide a framework for the first rational design of optimized strategies for human cardiac stem cell therapy. His group also works closely with the SFVAMC Cardiac Biomechanics Laboratory, headed by Drs. Mark Ratcliffe and Julius Guccione, which has developed among the world's most advanced computerized mathematical programs to model and predict the biophysics of cardiac function.
Together, they are applying these capabilities to better understand cell transplantation as well as the emerging field of surgical reconstruction of damaged hearts. In addition, Dr. Mann collaborates with Dr. Kevin Healy and other bioengineers from the UC Berkeley campus to apply novel artificial materials toward both the delivery of non-embryonic stem cells to intact hearts and the engineering of bioartificial heart tissue.
Selected Publications
-
Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A. 92: 4502-6, May/9/1995.
-
Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, Dzau VJ. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A. 96: 6411-6, May/25/1999.
-
Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354: 1493-8, Oct/30/1999.
-
Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol. 24: 845-50, May/2004.
-
Mann MJ, Tendulkar A, Birger N, Howard C. Ratcliffe MB. NIH funding for surgical research. Ann Surg. (In Press) , 2007.
In the News
Twenty-Five Department of Surgery Faculty Named to U.S. News “Top Doctors†List
U.S. News - Mar 01, 2012In its most recent survey, U.S. News in collaboration with Castle Connolly Medical Ltd. listed twenty-five (25) surgeons in the UCSF Department of Surgery, nearly one-third (1/3) of the clinical faculty, on the list of U.S. News "Top Doctors". The list, compiled from the opinion of colleagues, denotes the top 10% of physicians within a region practicing a given specialty. Fifteen of the 25 department surgeons were also named by their peers to the list of America's Top Doctors (ATD), a distinction reserved for the top 1% of physicians in the nation for that specialty. The listings are published online at U.S. News. The group rankings are intended to guide patients in selecting a doctor and physicians in making specialty referrals.
New Lung Cancer Test Better Predicts Survival
The Lancet - UCSF News Center - Medscape Medical News - Jan 26, 2012In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team, led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a molecular test could better predict the likelihood of recurrence and risk of death in patients who have undergone surgery for early-stage lung cancer, versus conventional NCCN staging guidelines. In comparison to earlier prognostic assays for lung cancer, this one, according to John Minna, M.D.", Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology at UT Southwestern stands "head and shoulders" above the rest and is ready for "prime time" clinical use.
New Lung Cancer Assay Ready for Prime Time (Medscape Oncology News)
New Lung Cancer Test Predicts Survival (by Jason Bardi - UCSF News Center)
Advancing the Treatment of Adult Soft Tissue Sarcomas
Orthopedic Surgery News at UCSF Medical Center - Dec 25, 2008"Soft tissue sarcomas are extraordinarily heterogeneous, so experience is particularly important when deciding among treatment options," says medical oncologist Thierry M. Jahan, M.D. (pictured right). At UCSF, referring physicians typically send patients with painful, growing soft tissue masses to orthopedic surgeon Richard J. O'Donnell, M.D., and general surgeon Eric K. Nakakura, M.D., Ph.D, (pictured left). If their initial examination convinces them that there is a sarcoma concern, they move on to a staging workup that includes various imaging modalities and, eventually, either a needle or incisional biopsy...."
The Problem of Funding in Surgical Research
Scientists and Engineers for America (SEA) - May 20, 2008"Surgeons may be capable of accelerating the translation of basic research into new clinical therapies. Nevertheless, most surgeon-scientists believe they are at a disadvantage in competing for peer-reviewed funding, despite a recent emphasis on "translational science" by organizations such as the NIH."
